Facebook
Twitter
LinkedIn
Forward
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|
What anti-obesity medications are in development?
|
In this co-presentation, we will explore the fascinating link between body composition changes, the use of anti-obesity medications, and the innovative approach of clinician-led obesity care.
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
As published and described in Obesity Pillars (i.e., the official journal of the Obesity Medicine Association), excessive weight reduction is an emerging challenge that sometimes arises with approv
|